Assessment of vaccinations and breakthrough infections after adjustment of the dynamic zero-COVID-19 strategy in China: an online survey

Abstract

Coronavirus disease 2019 (COVID-19) cases in China has grown rapidly after adjustment of the dynamic zero-COVID-19 strategy. However, how different vaccination states affect symptoms, severity and post COVID conditions was unclear. Here, we used an online questionnaire to investigate the infection status of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among 11,897 participants, with 55.55% positive and 28.42% negative. The common COVID-19 symptoms were fatigue (73.31%), cough (70.02%), fever (65.25%) and overall soreness (58.64%); self-reported asymptomatic infection accounted for 0.7% of participants. The persistent symptoms at 1 month after infection included fatigue (48.7%), drowsiness (34.3%), cough (30.1%), decreased exercise ability (23.1%) and pharyngeal discomfort (19.4%), which was reduced by more than 200% at 2 months. Participants with complications such as chronic obstructive pulmonary disease, respiratory diseases, diabetes, hypertension, etc. have a higher proportion of hospitalization and longer recovery time ( p < = 0.01). Multiple vaccination statuses reduced the infection ( p < 0.001) and severity rates ( p = 0.022) by varying degrees as well as reduced the risk of high fever (>39.1 °C), chills, diarrhea and ageusia/anosmia, respectively ( p < 0.05). Vaccination may enhance some upper respiratory symptoms, including sore throat, nasal congestion and runny nose, respectively ( p < 0.05). Participants who had been vaccinated within 3 months were better protected by helping reduce their risk of overall soreness, chills and ageusia/anosmia, respectively ( p < 0.05). In conclusion, our work has updated the epidemic characteristics of the breakthrough infection (BTI) wave after the dynamic zero-COVID-19 strategy, providing data and insights on how different vaccination statuses affect COVID-19 symptoms and disease prognosis.

Clinical and immunological features of COVID‐19 in patients with anti‐MDA5 dermatomyositis during the omicron wave in Chongqing, China

“…First, we evaluated the effect of anti‐MDA5 DM on COVID‐19 infection. In this study, 68.7% of patients with anti‐MDA5 DM reported a COVID‐19 infection between December 9, 2022 and March 31, 2023, which was higher than the infection rate observed in a recent study focused on the general population in China (55.55%) 26 . Hence, patients with anti‐MDA5 DM seem to be vulnerable to SARS‐CoV‐2.…”

“…The main findings of our study were as follows: (1) Vaccination did not provide protection against COVID-19 infection in patients with anti-MDA5 DM, but the symptoms of COVID-19 in patients with anti-MDA5 DM were generally mild; (2) COVID-19 infection did not exacerbate the progress of the disease in patients with anti-MDA5 DM; (3) the antibody response and MBC response were similar between HCs and patients with anti-MDA5 DM after COVID-19 infection, whereas the CD8 + T-cell response was impaired.First, we evaluated the effect of anti-MDA5 DM on COVID-19 infection. In this study, 68.7% of patients with anti-MDA5 DM reported a COVID-19 infection between December 9, 2022 and March 31, 2023, which was higher than the infection rate observed in a recent study focused on the general population in China (55.55%) 26. Hence, patients with anti-MDA5 DM seem to be vulnerable to SARS-CoV-2.…”

Risk of COVID‐19 infection and seizure exacerbation among patients with epilepsy during the peak of Omicron wave

“… 1 Additionally, a cross‐sectional analysis, including 11 897 participants from seven diverse regions across China, revealed an overall COVID‐19 positivity rate of 70.58%. 33 In light of the current data, PWE in our cohort do not appear to be disproportionately affected by the pandemic relative to the general population. Several potential explanations may contribute to this observation.…”

“…Secondly, studies focusing on other cohorts with more severe conditions that need hospitalization or with extended observation periods of 1–3 months often report relatively higher positivity rates. 1 , 33 …”

Analysis of Prognostic Factors and Establishment of a Nomogram to Predict Risk for COVID-19 Convalescent Patients Based on Metabolomic and Lipidomic

“…One year post-infection, 0.9% of patients continued to suffer from the consequences of COVID-19(Global Burden of Disease Long et al, 2022). Another study, encompassing 11,897 patients from seven regions in China, indicated that the incidence of long COVID-19 was nearly 50% (Qin et al, 2023). Subsequent research, involving 1,359 discharged COVID-19 patients, demonstrated that 54% of individuals still exhibited at least one long COVID symptom three years post-discharge.…”